This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murray, H. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murray, H. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2000, p. 3235-3236, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Suppression of Posttreatment Recurrence of Experimental Visceral Leishmaniasis in T-Cell-Deficient Mice by Oral Miltefosine

Henry W. Murray*

Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021

Received 19 April 2000/Returned for modification 5 June 2000/Accepted 5 August 2000

T-cell-deficient nude mice infected with Leishmania donovani were treated with miltefosine and then given either no treatment or intermittent miltefosine. Intracellular visceral infection recurred in untreated mice but was suppressed by once- or twice-weekly oral administration of miltefosine. Miltefosine may be useful as oral maintenance therapy for T-cell-deficient patients with visceral leishmaniasis.

* Mailing address: Department of Medicine, Weill Medical College of Cornell University, 1300 York Ave., New York, NY 10021. Phone: (212) 746-6330. Fax: (212) 746-6332. E-mail: hwmurray{at}mail.med.cornell.edu.

Antimicrobial Agents and Chemotherapy, November 2000, p. 3235-3236, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Alvar, J., Aparicio, P., Aseffa, A., Den Boer, M., Canavate, C., Dedet, J.-P., Gradoni, L., Ter Horst, R., Lopez-Velez, R., Moreno, J. (2008). The Relationship between Leishmaniasis and AIDS: the Second 10 Years. Clin. Microbiol. Rev. 21: 334-359 [Abstract] [Full Text]  
  • Rakotomanga, M., Blanc, S., Gaudin, K., Chaminade, P., Loiseau, P. M. (2007). Miltefosine Affects Lipid Metabolism in Leishmania donovani Promastigotes. Antimicrob. Agents Chemother. 51: 1425-1430 [Abstract] [Full Text]  
  • Murray, H. W. (2005). Prevention of Relapse after Chemotherapy in a Chronic Intracellular Infection: Mechanisms in Experimental Visceral Leishmaniasis. J. Immunol. 174: 4916-4923 [Abstract] [Full Text]  
  • Saraiva, V. B., Gibaldi, D., Previato, J. O., Mendonca-Previato, L., Bozza, M. T., Freire-de-Lima, C. G., Heise, N. (2002). Proinflammatory and Cytotoxic Effects of Hexadecylphosphocholine (Miltefosine) against Drug-Resistant Strains of Trypanosoma cruzi. Antimicrob. Agents Chemother. 46: 3472-3477 [Abstract] [Full Text]  
  • Murray, H. W. (2001). Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis. Antimicrob. Agents Chemother. 45: 2185-2197 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»